Attention-deficit Hyperactivity
3 drugs in development·3 companies·1 clinical trial
Drug Pipeline by Phase
Approved(1)
| Drug | Company |
|---|---|
| Qelbree | SUPERNUS PHARMACEUTICALS, INC. (SUPN) |
Phase 2(1)
| Drug | Company |
|---|---|
| ABV-1505 | ABVC BIOPHARMA, INC. (ABVC) |
Phase 1(1)
| Drug | Company |
|---|---|
| nfc-1 | AEVI GENOMIC MEDICINE, INC. (GNMX) |
Compare drugs
Frequently asked questions
How many drugs are in development for Attention-deficit Hyperactivity?
BioSniper tracks 3 drugs in development for Attention-deficit Hyperactivity across 3 companies.
How many clinical trials target Attention-deficit Hyperactivity?
There are 1 clinical trial targeting Attention-deficit Hyperactivity tracked by BioSniper.
Deep-dive into Attention-deficit Hyperactivity
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis